Artwork

Innhold levert av Labiotech. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Labiotech eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

How biotech is tackling myasthenia gravis

28:50
 
Del
 

Manage episode 419977836 series 3361449
Innhold levert av Labiotech. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Labiotech eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles.

It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older.

To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.

01:07-04:26: Background on Dr Dana Vigier
04:26-07:07: What is myasthenia gravis?
07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?
09:43-11:33: How effective are current treatments for myasthenia gravis?
11:33-12:56: Do all the myasthenia gravis drugs work in the same way?
12:56-18:35: What R&D is taking place in myasthenia gravis?
18:35-21:14: Alexion and its work on myasthenia gravis
21:14-22:01: Myasthenia gravis clinical trials
22:01-23:58: The importance of myasthenia gravis awareness month
23:58-25:31: Would early diagnosis make a difference?
25:31-27:54: Transformation through new treatments
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitler

1. How biotech is tackling myasthenia gravis (00:00:00)

2. Background on Dr Dana Vigier
 (00:01:07)

3. What is myasthenia gravis?
 (00:04:26)

4. What is the prognosis for someone diagnosed with myasthenia gravis?
 (00:07:07)

5. How effective are current treatments for myasthenia gravis?
 (00:09:43)

6. Do myasthenia gravis drugs work in the same way? 
 (00:11:33)

7. What R&D is taking place in myasthenia gravis?
 (00:12:56)

8. Alexion and its work on myasthenia gravis
 (00:18:35)

9. Myasthenia gravis clinical trials
 (00:21:14)

10. The importance of myasthenia gravis awareness month
 (00:22:01)

11. Would early diagnosis of myasthenia gravis make a difference? (00:23:58)

12. Transformation through new treatments (00:25:31)

131 episoder

Artwork
iconDel
 
Manage episode 419977836 series 3361449
Innhold levert av Labiotech. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Labiotech eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles.

It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older.

To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.

01:07-04:26: Background on Dr Dana Vigier
04:26-07:07: What is myasthenia gravis?
07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?
09:43-11:33: How effective are current treatments for myasthenia gravis?
11:33-12:56: Do all the myasthenia gravis drugs work in the same way?
12:56-18:35: What R&D is taking place in myasthenia gravis?
18:35-21:14: Alexion and its work on myasthenia gravis
21:14-22:01: Myasthenia gravis clinical trials
22:01-23:58: The importance of myasthenia gravis awareness month
23:58-25:31: Would early diagnosis make a difference?
25:31-27:54: Transformation through new treatments
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitler

1. How biotech is tackling myasthenia gravis (00:00:00)

2. Background on Dr Dana Vigier
 (00:01:07)

3. What is myasthenia gravis?
 (00:04:26)

4. What is the prognosis for someone diagnosed with myasthenia gravis?
 (00:07:07)

5. How effective are current treatments for myasthenia gravis?
 (00:09:43)

6. Do myasthenia gravis drugs work in the same way? 
 (00:11:33)

7. What R&D is taking place in myasthenia gravis?
 (00:12:56)

8. Alexion and its work on myasthenia gravis
 (00:18:35)

9. Myasthenia gravis clinical trials
 (00:21:14)

10. The importance of myasthenia gravis awareness month
 (00:22:01)

11. Would early diagnosis of myasthenia gravis make a difference? (00:23:58)

12. Transformation through new treatments (00:25:31)

131 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill